ATP binding cassette transporter A1 (ABCA1) associated proteins: Potential drug targets in the metabolic syndrome and atherosclerotic disease?

Current Pharmaceutical Biotechnology

Volumn 13, Issue 2, 2012, Pages 319-330

  Buechler, Christa ^a   Bauer, Sabrina ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Apolipoprotein; ATP binding cassette transporter; Chronic overnutrition

Indexed keywords

ABC TRANSPORTER A1; ALDEHYDE OXIDASE; ALDEHYDE OXIDASE 1; APOLIPOPROTEIN A1; CALPAIN; CAVEOLIN 1; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLOTILLIN 1; GLUTAMIC ACID; GUANINE NUCLEOTIDE EXCHANGE FACTOR; HIGH DENSITY LIPOPROTEIN; JANUS KINASE 2; PHOSPHOLIPID TRANSFER PROTEIN; PROLINE; PROTEIN CDC42; PROTEIN KINASE C; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SERINE; SERINE PALMITOYLTRANSFERASE; SERINE PALMITOYLTRANSFERASE 1; STAT3 PROTEIN; SYNTAXIN; SYNTAXIN 13; SYNTROPHIN; SYNTROPHIN ALPHA; SYNTROPHIN BETA 1; SYNTROPHIN BETA 2; THREONINE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; UTROPHIN;

AMINO ACID SEQUENCE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL STRAIN HEPG2; DRUG TARGETING; ENDOPLASMIC RETICULUM; ENDOSOME; ENDOTHELIUM CELL; EXOCYTOSIS; FIBROBLAST; HUMAN; INSULIN RESISTANCE; INTRACELLULAR TRANSPORT; LIPID RAFT; LIPID TRANSPORT; LIVER CELL; MACROPHAGE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN DEGRADATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; WERNER SYNDROME;

ANIMALS; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CHOLESTEROL; HUMANS; METABOLIC SYNDROME X; MOLECULAR TARGETED THERAPY;

EID: 84856493679     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112799095365     Document Type: Article

References (127)

1. Berghofer, A.; Pischon, T.; Reinhold, T.; Apovian, C.M.; Sharma, A.M.; Willich, S.N. Obesity prevalence from a European perspective: a systematic review. BMC Public Health, 2008, 8, 200.
2. Catenacci, V.A.; Hill, J.O.; Wyatt, H.R. The obesity epidemic. Clin. Chest Med., 2009, 30, 415-444, vii.
3. Ode, K.L.; Frohnert, B.I.; Nathan, B.M. Identification and treatment of metabolic complications in pediatric obesity. Rev. Endocr. Metab. Disord., 2009, 10, 167-188.
4. Lavie, C.J.; Milani, R.V.; Ventura, H.O. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J. Am. Coll. Cardiol., 2009, 53, 1925-1932.
5. Goossens, G.H. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol. Behav., 2008, 94, 206-218.
6. Schober, F.; Neumeier, M.; Weigert, J.; Wurm, S.; Wanninger, J.; Schaffler, A.; Dada, A.; Liebisch, G.; Schmitz, G.; Aslanidis, C.; Buechler, C. Low molecular weight adiponectin negatively correlates with the waist circumference and monocytic IL-6 release. Biochem. Biophys. Res. Commun., 2007, 361, 968-973.
7. Qureshi, K.; Abrams, G.A. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J. Gastroenterol., 2007, 13, 3540-3553.
8. Brunham, L.R.; Singaraja, R.R.; Duong, M.; Timmins, J.M.; Fievet, C.; Bissada, N.; Kang, M.H.; Samra, A.; Fruchart, J.C.; McManus, B.; Staels, B.; Parks, J.S.; Hayden, M.R. Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis. Arterioscler Thromb. Vasc. Biol., 2009, 29, 548-554.
9. Feig, J.E.; Shamir, R.; Fisher, E.A. Atheroprotective effects of HDL: beyond reverse cholesterol transport. Curr. Drug Targets, 2008, 9, 196-203.
10. Yvan-Charvet, L.; Wang, N.; Tall, A.R. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb. Vasc. Biol., 2010, 30, 139-143.
11. Bodzioch, M.; Orso, E.; Klucken, J.; Langmann, T.; Bottcher, A.; Diederich, W.; Drobnik, W.; Barlage, S.; Buchler, C.; Porsch-Ozcurumez, M.; Kaminski, W.E.; Hahmann, H.W.; Oette, K.; Rothe, G.; Aslanidis, C.; Lackner, K.J.; Schmitz, G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet., 1999, 22, 347-351.
12. Brooks-Wilson, A.; Marcil, M.; Clee, S.M.; Zhang, L.H.; Roomp, K.; van Dam, M.; Yu, L.; Brewer, C.; Collins, J.A.; Molhuizen, H.O.; Loubser, O.; Ouelette, B.F.; Fichter, K.; Ashbourne-Excoffon, K.J.; Sensen, C.W.; Scherer, S.; Mott, S.; Denis, M.; Martindale, D.; Frohlich, J.; Morgan, K.; Koop, B.; Pimstone, S.; Kastelein, J.J.; Genest, J., Jr.; Hayden, M.R. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet., 1999, 22, 336-345.
13. Rust, S.; Rosier, M.; Funke, H.; Real, J.; Amoura, Z.; Piette, J.C.; Deleuze, J.F.; Brewer, H.B.; Duverger, N.; Denefle, P.; Assmann, G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet., 1999, 22, 352-355.
14. Rader, D.J.; Alexander, E.T.; Weibel, G.L.; Billheimer, J.; Rothblat, G.H. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res., 2009, 50(Suppl), S189-194.
15. Rothblat, G.H.; Phillips, M.C. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr. Opin. Lipidol., 2010, 21, 229-238.
16. Yang, Y.; Jiang, Y.; Wang, Y.; An, W. Suppression of ABCA1 by unsaturated fatty acids leads to lipid accumulation in HepG2 cells. Biochimie, 2010.
17. Toledo, F.G.; Sniderman, A.D.; Kelley, D.E. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care., 2006, 29, 1845-1850.
18. Ma, K.L.; Ruan, X.Z.; Powis, S.H.; Chen, Y.; Moorhead, J.F.; Varghese, Z. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology, 2008, 48, 770-781.
19. Lundberg, A.M.; Hansson, G.K. Innate immune signals in atherosclerosis. Clin. Immunol., 2010, 134, 5-24.
20. Tang, C.; Oram, J.F. The cell cholesterol exporter ABCA1 as a protector from cardiovascular disease and diabetes. Biochim. Biophys. Acta, 2009, 1791, 563-572.
21. Teixeira Carvalho, M.D.; Vieira Vendrame, C.M.; Jacon Ketelhuth, D.F.; Yamashiro-Kanashiro, E.H.; Goto, H.; Gidlund, M. High-Density Lipoprotein Inhibits the Uptake of Modified Low-Density Lipoprotein and the Expression of CD36 and FcgammaRI. J. Atheroscler Thromb., 2010.
22. Tang, C.; Liu, Y.; Kessler, P.S.; Vaughan, A.M.; Oram, J.F. The macrophage cholesterol exporter ABCA1 functions as an antiinflammatory receptor. J. Biol. Chem., 2009, 284, 32336-32343.
23. Mauerer, R.; Ebert, S.; Langmann, T. High glucose, unsaturated and saturated fatty acids differentially regulate expression of ATPbinding cassette transporters ABCA1 and ABCG1 in human macrophages. Exp. Mol. Med., 2009, 41, 126-132.
24. Wang, Y.; Oram, J.F. Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATPbinding cassette transporter A1. J. Biol. Chem., 2002, 277, 5692-5697.
25. Choi, H.Y.; Rahmani, M.; Wong, B.W.; Allahverdian, S.; McManus, B.M.; Pickering, J.G.; Chan, T.; Francis, G.A. ATPbinding cassette transporter A1 expression and apolipoprotein A-I binding are impaired in intima-type arterial smooth muscle cells. Circulation, 2009, 119, 3223-3231.
26. Francone, O.L.; Royer, L.; Boucher, G.; Haghpassand, M.; Freeman, A.; Brees, D.; Aiello, R.J. Increased cholesterol deposition, expression of scavenger receptors, and response to chemotactic factors in Abca1-deficient macrophages. Arterioscler Thromb. Vasc. Biol., 2005, 25, 1198-1205.
27. Yvan-Charvet, L.; Welch, C.; Pagler, T.A.; Ranalletta, M.; Lamkanfi, M.; Han, S.; Ishibashi, M.; Li, R.; Wang, N.; Tall, A.R. Increased inflammatory gene expression in ABC transporterdeficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation, 2008, 118, 1837-1847.
28. Mauldin, J.P.; Nagelin, M.H.; Wojcik, A.J.; Srinivasan, S.; Skaflen, M.D.; Ayers, C.R.; McNamara, C.A.; Hedrick, C.C. Reduced expression of ATP-binding cassette transporter G1 increases cholesterol accumulation in macrophages of patients with type 2 diabetes mellitus. Circulation, 2008, 117, 2785-2792.
29. Brunham, L.R.; Kruit, J.K.; Pape, T.D.; Timmins, J.M.; Reuwer, A.Q.; Vasanji, Z.; Marsh, B.J.; Rodrigues, B.; Johnson, J.D.; Parks, J.S.; Verchere, C.B.; Hayden, M.R. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat. Med., 2007, 13, 340-347.
30. Koseki, M.; Matsuyama, A.; Nakatani, K.; Inagaki, M.; Nakaoka, H.; Kawase, R.; Yuasa-Kawase, M.; Tsubakio-Yamamoto, K.; Masuda, D.; Sandoval, J.C.; Ohama, T.; Nakagawa-Toyama, Y.; Matsuura, F.; Nishida, M.; Ishigami, M.; Hirano, K.; Sakane, N.; Kumon, Y.; Suehiro, T.; Nakamura, T.; Shimomura, I.; Yamashita, S. Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations. J. Atheroscler Thromb., 2009, 16, 292-296.
31. Calkin, A.C.; Drew, B.G.; Ono, A.; Duffy, S.J.; Gordon, M.V.; Schoenwaelder, S.M.; Sviridov, D.; Cooper, M.E.; Kingwell, B.A.; Jackson, S.P. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation, 2009, 120, 2095-2104.
32. Shaw, J.A.; Bobik, A.; Murphy, A.; Kanellakis, P.; Blombery, P.; Mukhamedova, N.; Woollard, K.; Lyon, S.; Sviridov, D.; Dart, A.M. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ. Res., 2008, 103, 1084-1091.
33. Sethi, A.A.; Stonik, J.A.; Thomas, F.; Demosky, S.J.; Amar, M.; Neufeld, E.; Brewer, H.B.; Davidson, W.S.; D'Souza, W.; Sviridov, D.; Remaley, A.T. Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J. Biol. Chem., 2008, 283, 32273-32282.
34. Navab, M.; Anantharamaiah, G.M.; Reddy, S.T.; Hama, S.; Hough, G.; Grijalva, V.R.; Yu, N.; Ansell, B.J.; Datta, G.; Garber, D.W.; Fogelman, A.M. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb. Vasc. Biol., 2005, 25, 1325-1331.
35. DeLeve, L.D.; Wang, X.; Kanel, G.C.; Atkinson, R.D.; McCuskey, R.S. Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. Am. J. Pathol., 2008, 173, 993-1001.
36. Bloedon, L.T.; Dunbar, R.; Duffy, D.; Pinell-Salles, P.; Norris, R.; DeGroot, B.J.; Movva, R.; Navab, M.; Fogelman, A.M.; Rader, D.J. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J. Lipid Res., 2008, 49, 1344-1352.
37. Vedhachalam, C.; Narayanaswami, V.; Neto, N.; Forte, T.M.; Phillips, M.C.; Lund-Katz, S.; Bielicki, J.K. The C-terminal lipidbinding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins. Biochemistry, 2007, 46, 2583-2593.
38. Bielicki, J.K.; Zhang, H.; Cortez, Y.; Zheng, Y.; Narayanaswami, V.; Patel, A.; Johansson, J.; Azhar, S. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J. Lipid Res., 2010, 51, 1496-1503.
39. Fitzgerald, M.L.; Mujawar, Z.; Tamehiro, N. ABC transporters, atherosclerosis and inflammation. Atherosclerosis, 2010, 211:361-370.
40. Chen, W.; Wang, N.; Tall, A.R. A PEST deletion mutant of ABCA1 shows impaired internalization and defective cholesterol efflux from late endosomes. J. Biol. Chem., 2005, 280, 29277-29281.
41. Singaraja, R.R.; Kang, M.H.; Vaid, K.; Sanders, S.S.; Vilas, G.L.; Arstikaitis, P.; Coutinho, J.; Drisdel, R.C.; El-Husseini Ael, D.; Green, W.N.; Berthiaume, L.; Hayden, M.R. Palmitoylation of ATP-binding cassette transporter A1 is essential for its trafficking and function. Circ. Res., 2009, 105, 138-147.
42. Landry, Y.D.; Denis, M.; Nandi, S.; Bell, S.; Vaughan, A.M.; Zha, X. ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. J. Biol. Chem., 2006, 281, 36091-36101.
43. Vaughan, A.M.; Oram, J.F. ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions. J. Lipid Res., 2003, 44, 1373-1380.
44. Tang, C.; Vaughan, A.M.; Oram, J.F. Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol. J. Biol. Chem., 2004, 279, 7622-7628.
45. Pownall, H.J.; Hosken, B.D.; Gillard, B.K.; Higgins, C.L.; Lin, H.Y.; Massey, J.B. Speciation of human plasma high-density lipoprotein (HDL): HDL stability and apolipoprotein A-I partitioning. Biochemistry, 2007, 46, 7449-7459.
46. Arakawa, R.; Yokoyama, S. Helical apolipoproteins stabilize ATPbinding cassette transporter A1 by protecting it from thiol proteasemediated degradation. J. Biol. Chem., 2002, 277, 22426-22429.
47. Remaley, A.T.; Stonik, J.A.; Demosky, S.J.; Neufeld, E.B.; Bocharov, A.V.; Vishnyakova, T.G.; Eggerman, T.L.; Patterson, A.P.; Duverger, N.J.; Santamarina-Fojo, S.; Brewer, H.B., Jr. Apolipoprotein specificity for lipid efflux by the human ABCAI transporter. Biochem. Biophys. Res. Commun., 2001, 280, 818-823.
48. Schmitz, G.; Grandl, M. The molecular mechanisms of HDL and associated vesicular trafficking mechanisms to mediate cellular lipid homeostasis. Arterioscler Thromb. Vasc. Biol., 2009, 29, 1718-1722.
49. Arakawa, R.; Hayashi, M.; Remaley, A.T.; Brewer, B.H.; Yamauchi, Y.; Yokoyama, S. Phosphorylation and stabilization of ATP binding cassette transporter A1 by synthetic amphiphilic helical peptides. J. Biol. Chem., 2004, 279, 6217-6220.
50. Remaley, A.T.; Thomas, F.; Stonik, J.A.; Demosky, S.J.; Bark, S.E.; Neufeld, E.B.; Bocharov, A.V.; Vishnyakova, T.G.; Patterson, A.P.; Eggerman, T.L.; Santamarina-Fojo, S.; Brewer, H.B. Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J. Lipid Res., 2003, 44, 828-836.
51. Sherman, C.B.; Peterson, S.J.; Frishman, W.H. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol. Rev., 2010, 18, 141-147.
52. Krimbou, L.; Denis, M.; Haidar, B.; Carrier, M.; Marcil, M.; Genest, J., Jr. Molecular interactions between apoE and ABCA1: impact on apoE lipidation. J. Lipid Res., 2004, 45, 839-848.
53. Fan, J.; Donkin, J.; Wellington, C. Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E. Biofactors, 2009, 35, 239-248.
54. Handattu, S.P.; Garber, D.W.; Monroe, C.E.; van Groen, T.; Kadish, I.; Nayyar, G.; Cao, D.; Palgunachari, M.N.; Li, L.; Anantharamaiah, G.M. Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. Neurobiol. Dis., 2009, 34, 525-534.
55. Wahrle, S.E.; Jiang, H.; Parsadanian, M.; Kim, J.; Li, A.; Knoten, A.; Jain, S.; Hirsch-Reinshagen, V.; Wellington, C.L.; Bales, K.R.; Paul, S.M.; Holtzman, D.M. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest., 2008, 118, 671-682.
56. Tzotzas, T.; Desrumaux, C.; Lagrost, L. Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor. Obes. Rev., 2009, 10, 403-411.
57. Oram, J.F.; Wolfbauer, G.; Tang, C.; Davidson, W.S.; Albers, J.J. An amphipathic helical region of the N-terminal barrel of phospholipid transfer protein is critical for ABCA1-dependent cholesterol efflux. J. Biol. Chem., 2008, 283, 11541-11549.
58. Oram, J.F.; Wolfbauer, G.; Vaughan, A.M.; Tang, C.; Albers, J.J. Phospholipid transfer protein interacts with and stabilizes ATPbinding cassette transporter A1 and enhances cholesterol efflux from cells. J. Biol. Chem., 2003, 278, 52379-52385.
59. Nofer, J.R.; Feuerborn, R.; Levkau, B.; Sokoll, A.; Seedorf, U.; Assmann, G. Involvement of Cdc42 signaling in apoA-I-induced cholesterol efflux. J. Biol. Chem., 2003, 278, 53055-53062.
60. Tang, C.; Vaughan, A.M.; Anantharamaiah, G.M.; Oram, J.F. Janus kinase 2 modulates the lipid-removing but not proteinstabilizing interactions of amphipathic helices with ABCA1. J. Lipid Res., 2006, 47, 107-114.
61. Yamauchi, Y.; Hayashi, M.; Abe-Dohmae, S.; Yokoyama, S. Apolipoprotein A-I activates protein kinase C alpha signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly. J. Biol. Chem., 2003, 278, 47890-47897.
62. Grote, K.; Luchtefeld, M.; Schieffer, B. JANUS under stress--role of JAK/STAT signaling pathway in vascular diseases. Vascul. Pharmacol., 2005, 43, 357-363.
63. Williams, L.M.; Sarma, U.; Willets, K.; Smallie, T.; Brennan, F.; Foxwell, B.M. Expression of constitutively active STAT3 can replicate the cytokine-suppressive activity of interleukin-10 in human primary macrophages. J. Biol. Chem., 2007, 282, 6965-6975.
64. Koseki, M.; Hirano, K.; Masuda, D.; Ikegami, C.; Tanaka, M.; Ota, A.; Sandoval, J.C.; Nakagawa-Toyama, Y.; Sato, S.B.; Kobayashi, T.; Shimada, Y.; Ohno-Iwashita, Y.; Matsuura, F.; Shimomura, I.; Yamashita, S. Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor-alpha secretion in Abca1-deficient macrophages. J. Lipid Res., 2007, 48, 299-306.
65. Wong, S.W.; Kwon, M.J.; Choi, A.M.; Kim, H.P.; Nakahira, K.; Hwang, D.H. Fatty acids modulate Toll-like receptor 4 activation through regulation of receptor dimerization and recruitment into lipid rafts in a reactive oxygen species-dependent manner. J. Biol. Chem., 2009, 284, 27384-27392.
66. Shi, H.; Kokoeva, M.V.; Inouye, K.; Tzameli, I.; Yin, H.; Flier, J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest., 2006, 116, 3015-3025.
67. Xie, Q.; Zhao, S.P.; Li, F. D-4F, an apolipoprotein A-I mimetic peptide, promotes cholesterol efflux from macrophages via ATPbinding cassette transporter A1. Tohoku J. Exp. Med., 2010, 220, 223-228.
68. Takai, Y.; Sasaki, T.; Matozaki, T. Small GTP-binding proteins. Physiol. Rev., 2001, 81, 153-208.
69. Hirano, K.; Matsuura, F.; Tsukamoto, K.; Zhang, Z.; Matsuyama, A.; Takaishi, K.; Komuro, R.; Suehiro, T.; Yamashita, S.; Takai, Y.; Matsuzawa, Y. Decreased expression of a member of the Rho GTPase family, Cdc42Hs, in cells from Tangier disease-the small G protein may play a role in cholesterol efflux. FEBS Lett., 2000, 484, 275-279.
70. Nofer, J.R.; Remaley, A.T.; Feuerborn, R.; Wolinnska, I.; Engel, T.; von Eckardstein, A.; Assmann, G. Apolipoprotein A-I activates Cdc42 signaling through the ABCA1 transporter. J. Lipid Res., 2006, 47, 794-803.
71. Tsukamoto, K.; Hirano, K.; Tsujii, K.; Ikegami, C.; Zhongyan, Z.; Nishida, Y.; Ohama, T.; Matsuura, F.; Yamashita, S.; Matsuzawa, Y. ATP-binding cassette transporter-1 induces rearrangement of actin cytoskeletons possibly through Cdc42/N-WASP. Biochem. Biophys. Res. Commun., 2001, 287, 757-765.
72. Tsukamoto, K.; Hirano, K.; Yamashita, S.; Sakai, N.; Ikegami, C.; Zhang, Z.; Matsuura, F.; Hiraoka, H.; Matsuyama, A.; Ishigami, M.; Matsuzawa, Y. Retarded intracellular lipid transport associated with reduced expression of Cdc42, a member of Rho-GTPases, in human aged skin fibroblasts: a possible function of Cdc42 in mediating intracellular lipid transport. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 1899-1904.
73. Zhang, Z.; Hirano, K.; Tsukamoto, K.; Ikegami, C.; Koseki, M.; Saijo, K.; Ohno, T.; Sakai, N.; Hiraoka, H.; Shimomura, I.; Yamashita, S. Defective cholesterol efflux in Werner syndrome fibroblasts and its phenotypic correction by Cdc42, a RhoGTPase. Exp. Gerontol., 2005, 40, 286-294.
74. Kowluru, A. Small G proteins in islet beta-cell function. Endocr. Rev. 2010, 31, 52-78.
75. Bezprozvanny, I.; Maximov, A. PDZ domains: More than just a glue. Proc. Natl. Acad. Sci. U S A., 2001, 98, 787-789.
76. Buechler, C.; Boettcher, A.; Bared, S.M.; Probst, M.C.; Schmitz, G. The carboxyterminus of the ATP-binding cassette transporter A1 interacts with a beta2-syntrophin/utrophin complex. Biochem. Biophys. Res. Commun., 2002, 293, 759-765.
77. Hegedus, T.; Sessler, T.; Scott, R.; Thelin, W.; Bakos, E.; Varadi, A.; Szabo, K.; Homolya, L.; Milgram, S.L.; Sarkadi, B. C-terminal phosphorylation of MRP2 modulates its interaction with PDZ proteins. Biochem. Biophys. Res. Commun., 2003, 302, 454-461.
78. Okuhira, K.; Fitzgerald, M.L.; Sarracino, D.A.; Manning, J.J.; Bell, S.A.; Goss, J.L.; Freeman, M.W. Purification of ATP-binding cassette transporter A1 and associated binding proteins reveals the importance of beta1-syntrophin in cholesterol efflux. J. Biol. Chem., 2005, 280, 39653-39664.
79. Tamehiro, N.; Zhou, S.; Okuhira, K.; Benita, Y.; Brown, C.E.; Zhuang, D.Z.; Latz, E.; Hornemann, T.; von Eckardstein, A.; Xavier, R.J.; Freeman, M.W.; Fitzgerald, M.L. SPTLC1 binds ABCA1 to negatively regulate trafficking and cholesterol efflux activity of the transporter. Biochemistry, 2008, 47, 6138-6147.
80. Froehner, S.C.; Adams, M.E.; Peters, M.F.; Gee, S.H. Syntrophins: modular adapter proteins at the neuromuscular junction and the sarcolemma. Soc. Gen. Physiol. Ser., 1997, 52, 197-207.
81. Munehira, Y.; Ohnishi, T.; Kawamoto, S.; Furuya, A.; Shitara, K.; Imamura, M.; Yokota, T.; Takeda, S.; Amachi, T.; Matsuo, M.; Kioka, N.; Ueda, K. Alpha1-syntrophin modulates turnover of ABCA1. J. Biol. Chem., 2004, 279, 15091-15095.
82. Fitzgerald, M.L.; Okuhira, K.; Short, G.F., 3rd; Manning, J.J.; Bell, S.A.; Freeman, M.W. ATP-binding cassette transporter A1 contains a novel C-terminal VFVNFA motif that is required for its cholesterol efflux and ApoA-I binding activities. J. Biol. Chem., 2004, 279, 48477-48485.
83. Basso, F.; Freeman, L.; Knapper, C.L.; Remaley, A.; Stonik, J.; Neufeld, E.B.; Tansey, T.; Amar, M.J.; Fruchart-Najib, J.; Duverger, N.; Santamarina-Fojo, S.; Brewer, H.B., Jr. Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J. Lipid Res., 2003, 44, 296-302.
84. Neufeld, E.B.; Stonik, J.A.; Demosky, S.J., Jr.; Knapper, C.L.; Combs, C.A.; Cooney, A.; Comly, M.; Dwyer, N.; Blanchette-Mackie, J.; Remaley, A.T.; Santamarina-Fojo, S.; Brewer, H.B., Jr. The ABCA1 transporter modulates late endocytic trafficking: insights from the correction of the genetic defect in Tangier disease. J. Biol. Chem., 2004, 279, 15571-15578.
85. Morais Cabral, J.H.; Petosa, C.; Sutcliffe, M.J.; Raza, S.; Byron, O.; Poy, F.; Marfatia, S.M.; Chishti, A.H.; Liddington, R.C. Crystal structure of a PDZ domain. Nature, 1996, 382, 649-652.
86. Ort, T.; Voronov, S.; Guo, J.; Zawalich, K.; Froehner, S.C.; Zawalich, W.; Solimena, M. Dephosphorylation of beta2-syntrophin and Ca2+/mu-calpain-mediated cleavage of ICA512 upon stimulation of insulin secretion. EMBO J., 2001, 20, 4013-4023.
87. Schmidt, A.; Hall, A. Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev., 2002, 16, 1587-1609.
88. Fukuhara, S.; Murga, C.; Zohar, M.; Igishi, T.; Gutkind, J.S. A novel PDZ domain containing guanine nucleotide exchange factor links heterotrimeric G proteins to Rho. J. Biol. Chem., 1999, 274, 5868-5879.
89. Okuhira, K.; Fitzgerald, M.L.; Tamehiro, N.; Ohoka, N.; Suzuki, K.; Sawada, J.I.; Naito, M.; Nishimaki-Mogami, T. Binding of PDZ-RhoGEF to ATP-binding cassette transporter A1 (ABCA1) induces cholesterol efflux through RhoA activation and prevention of transporter degradation. J. Biol. Chem., 2010, 285, 16369-16377.
90. Utech, M.; Hobbel, G.; Rust, S.; Reinecke, H.; Assmann, G.; Walter, M. Accumulation of RhoA, RhoB, RhoG, and Rac1 in fibroblasts from Tangier disease subjects suggests a regulatory role of Rho family proteins in cholesterol efflux. Biochem. Biophys. Res. Commun., 2001, 280, 229-236.
91. Smoak, K.; Madenspacher, J.; Jeyaseelan, S.; Williams, B.; Dixon, D.; Poch, K.R.; Nick, J.A.; Worthen, G.S.; Fessler, M.B. Effects of liver X receptor agonist treatment on pulmonary inflammation and host defense. J. Immunol., 2008, 180, 3305-3312.
92. Takano, H.; Komuro, I. Peroxisome proliferator-activated receptor gamma and cardiovascular diseases. Circ. J., 2009, 73, 214-220.
93. Buechler, C.; Bared, S.M.; Aslanidis, C.; Ritter, M.; Drobnik, W.; Schmitz, G. Molecular and functional interaction of the ATPbinding cassette transporter A1 with Fas-associated death domain protein. J. Biol. Chem., 2002, 277, 41307-41310.
94. Sigruener, A.; Buechler, C.; Orso, E.; Hartmann, A.; Wild, P.J.; Terracciano, L.; Roncalli, M.; Bornstein, S.R.; Schmitz, G. Human aldehyde oxidase 1 interacts with ATP-binding cassette transporter-1 and modulates its activity in hepatocytes. Horm. Metab. Res., 2007, 39, 781-789.
95. Drobnik, W.; Liebisch, G.; Biederer, C.; Trmbach, B.; Rogler, G.; Muller, P.; Schmitz, G. Growth and cell cycle abnormalities of fibroblasts from Tangier disease patients. Arterioscler Thromb. Vasc. Biol., 1999, 19, 28-38.
96. Hueber, A.O.; Zornig, M.; Bernard, A.M.; Chautan, M.; Evan, G. A dominant negative Fas-associated death domain protein mutant inhibits proliferation and leads to impaired calcium mobilization in both T-cells and fibroblasts. J. Biol. Chem., 2000, 275, 10453-10462.
97. Garattini, E.; Fratelli, M.; Terao, M. Mammalian aldehyde oxidases: genetics, evolution and biochemistry. Cell Mol. Life Sci., 2008, 65, 1019-1048.
98. Kitamura, S.; Sugihara, K.; Ohta, S. Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab. Pharmacokinet., 2006, 21, 83-98.
99. Neumeier, M.; Weigert, J.; Schaffler, A.; Weiss, T.S.; Schmidl, C.; Buttner, R.; Bollheimer, C.; Aslanidis, C.; Scholmerich, J.; Buechler, C. Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro. Biochem. Biophys. Res. Commun., 2006, 350, 731-735.
100. Weigert, J.; Neumeier, M.; Bauer, S.; Mages, W.; Schnitzbauer, A.A.; Obed, A.; Groschl, B.; Hartmann, A.; Schaffler, A.; Aslanidis, C.; Scholmerich, J.; Buechler, C. Small-interference RNA-mediated knock-down of aldehyde oxidase 1 in 3T3-L1 cells impairs adipogenesis and adiponectin release. FEBS Lett., 2008, 582, 2965-2972.
101. Neufeld, E.B.; Remaley, A.T.; Demosky, S.J.; Stonik, J.A.; Cooney, A.M.; Comly, M.; Dwyer, N.K.; Zhang, M.; Blanchette-Mackie, J.; Santamarina-Fojo, S.; Brewer, H.B., Jr. Cellular localization and trafficking of the human ABCA1 transporter. J. Biol. Chem., 2001, 276, 27584-27590.
102. Wang, N.; Chen, W.; Linsel-Nitschke, P.; Martinez, L.O.; Agerholm-Larsen, B.; Silver, D.L.; Tall, A.R. A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. J. Clin. Invest., 2003, 111, 99-107.
103. Lu, R.; Arakawa, R.; Ito-Osumi, C.; Iwamoto, N.; Yokoyama, S. ApoA-I facilitates ABCA1 recycle/accumulation to cell surface by inhibiting its intracellular degradation and increases HDL generation. Arterioscler Thromb. Vasc. Biol., 2008, 28, 1820-1824.
104. Iwamoto, N.; Lu, R.; Tanaka, N.; Abe-Dohmae, S.; Yokoyama, S. Calmodulin Interacts With ATP Binding Cassette Transporter A1 to Protect From Calpain-Mediated Degradation and Upregulates High-Density Lipoprotein Generation. Arterioscler Thromb. Vasc. Biol., 2010, 30, 1446-1452.
105. Hanada, K. Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. Biochim. Biophys. Acta., 2003, 1632, 16-30.
106. Glaros, E.N.; Kim, W.S.; Garner, B. Myriocin-mediated upregulation of hepatocyte apoA-I synthesis is associated with ERK inhibition. Clin. Sci. (Lond)., 2010, 118, 727-736.
107. Park, T.S.; Panek, R.L.; Mueller, S.B.; Hanselman, J.C.; Rosebury, W.S.; Robertson, A.W.; Kindt, E.K.; Homan, R.; Karathanasis, S.K.; Rekhter, M.D. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation., 2004, 110, 3465-3471.
108. Lyn-Cook, L.E., Jr.; Lawton, M.; Tong, M.; Silbermann, E.; Longato, L.; Jiao, P.; Mark, P.; Wands, J.R.; Xu, H.; de la Monte, S.M. Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. J. Alzheimers Dis., 2009, 16, 715-729.
109. Li, Z.; Park, T.S.; Li, Y.; Pan, X.; Iqbal, J.; Lu, D.; Tang, W.; Yu, L.; Goldberg, I.J.; Hussain, M.M.; Jiang, X.C. Serine palmitoyltransferase (SPT) deficient mice absorb less cholesterol. Biochim. Biophys. Acta., 2009, 1791, 297-306.
110. Bared, S.M.; Buechler, C.; Boettcher, A.; Dayoub, R.; Sigruener, A.; Grandl, M.; Rudolph, C.; Dada, A.; Schmitz, G. Association of ABCA1 with syntaxin 13 and flotillin-1 and enhanced phagocytosis in tangier cells. Mol. Biol. Cell., 2004, 15, 5399-5407.
111. Prekeris, R.; Klumperman, J.; Chen, Y.A.; Scheller, R.H. Syntaxin 13 mediates cycling of plasma membrane proteins via tubulovesicular recycling endosomes. J. Cell Biol., 1998, 143, 957-971.
112. Sigruener, A.; Buechler, C.; Bared, S.M.; Grandl, M.; Aslanidis, C.; Ugocsai, P.; Gehrmann, M.; Schmitz, G. E-LDL upregulates TOSO expression and enhances the survival of human macrophages. Biochem. Biophys. Res. Commun., 2007, 359, 723-728.
113. Williams, T.M.; Lisanti, M.P. The caveolin proteins. Genome Biol., 2004, 5, 214.
114. Fu, Y.; Hoang, A.; Escher, G.; Parton, R.G.; Krozowski, Z.; Sviridov, D. Expression of caveolin-1 enhances cholesterol efflux in hepatic cells. J. Biol. Chem., 2004, 279, 14140-14146.
115. Chao, W.T.; Tsai, S.H.; Lin, Y.C.; Lin, W.W.; Yang, V.C. Cellular localization and interaction of ABCA1 and caveolin-1 in aortic endothelial cells after HDL incubation. Biochem. Biophys. Res. Commun., 2005, 332, 743-749.
116. Lin, Y.C.; Ma, C.; Hsu, W.C.; Lo, H.F.; Yang, V.C. Molecular interaction between caveolin-1 and ABCA1 on high-density lipoprotein-mediated cholesterol efflux in aortic endothelial cells. Cardiovasc. Res., 2007, 75, 575-583.
117. Lin, Y.C.; Lin, C.H.; Kuo, C.Y.; Yang, V.C. ABCA1 modulates the oligomerization and Golgi exit of caveolin-1 during HDL-mediated cholesterol efflux in aortic endothelial cells. Biochem. Biophys. Res. Commun., 2009, 382, 189-195.
118. Frank, P.G.; Cheung, M.W.; Pavlides, S.; Llaverias, G.; Park, D.S.; Lisanti, M.P. Caveolin-1 and regulation of cellular cholesterol homeostasis. Am. J. Physiol. Heart Circ. Physiol., 2006, 291, H677-686.
119. Garrean, S.; Gao, X.P.; Brovkovych, V.; Shimizu, J.; Zhao, Y.Y.; Vogel, S.M.; Malik, A.B. Caveolin-1 regulates NF-kappaB activation and lung inflammatory response to sepsis induced by lipopolysaccharide. J. Immunol., 2006, 177, 4853-4860.
120. Cheng, J.; Van Norstrand, D.W.; Medeiros-Domingo, A.; Valdivia, C.; Tan, B.H.; Ye, B.; Kroboth, S.; Vatta, M.; Tester, D.J.; January, C.T.; Makielski, J.C.; Ackerman, M.J. Alpha1-syntrophin mutations identified in sudden infant death syndrome cause an increase in late cardiac sodium current. Circ. Arrhythm Electrophysiol., 2009, 2, 667-676.
121. Schmitz, G.; Buechler, C. ABCA1: regulation, trafficking and association with heteromeric proteins. Ann. Med., 2002, 34, 334-347.
122. Adams, M.E.; Kramarcy, N.; Fukuda, T.; Engel, A.G.; Sealock, R.; Froehner, S.C. Structural abnormalities at neuromuscular synapses lacking multiple syntrophin isoforms. J. Neurosci., 2004, 24, 10302-10309.
123. Kasza, I.; Hegyi, Z.; Szabo, K.; Andrikovics, H.; Nemet, K.; Varadi, A.; Sarkadi, B.; Homolya, L. Model system for the analysis of cell surface expression of human ABCA1. BMC Cell Biol., 2009, 10, 93.
124. Mangas, A.; Covenas, R.; Geffard, M. New drug therapies for multiple sclerosis. Curr. Opin Neurol., 2010, 23, 287-292.
125. Watson, M.L.; Coghlan, M.; Hundal, H.S. Modulating serine palmitoyl transferase (SPT) expression and activity unveils a crucial role in lipid-induced insulin resistance in rat skeletal muscle cells. Biochem. J., 2009, 417, 791-801.
126. Sinha, S.; Yang, W. Cellular signaling for activation of Rho GTPase Cdc42. Cell Signal., 2008, 20, 1927-1934.
127. van Golen, K.L. Is caveolin-1 a viable therapeutic target to reduce cancer metastasis? Expert Opin. Ther. Targets, 2006, 10, 709-721.